{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:09:49Z","timestamp":1791835789588,"version":"4.3.4"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2014,6,18]],"date-time":"2014-06-18T00:00:00Z","timestamp":1403049600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s11926-014-0437-4","type":"journal-article","created":{"date-parts":[[2014,6,19]],"date-time":"2014-06-19T12:08:56Z","timestamp":1403179736000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis"],"prefix":"10.1007","volume":"16","author":[{"given":"Rosa","family":"Bou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Est\u00edbaliz","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Ant\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,18]]},"reference":[{"key":"437_CR1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00417-005-0087-3","volume":"244","author":"PE Carvounis","year":"2006","unstructured":"Carvounis PE, Herman DC, Cha S, Burke JP. Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature. Graefes Arch Clin Exp Ophthalmol. 2006;244:281\u201390.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"437_CR2","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S0002-9394(03)00104-1","volume":"135","author":"RE Petty","year":"2003","unstructured":"Petty RE, Smith JR, Rosenbaum JT. Arthritis and uveitis in children: A pediatric rheumatology perspective. Am J Ophthalmol. 2003;135:879\u201384.","journal-title":"Am J Ophthalmol"},{"key":"437_CR3","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jaapos.2008.03.007","volume":"12","author":"K Sabri","year":"2008","unstructured":"Sabri K, Saurenmann RK, Silverman ED, Levin AV. Course, complications, and outcome of juvenile arthritis-related uveitis. J AAPOS. 2008;12:539\u201345.","journal-title":"J AAPOS"},{"key":"437_CR4","doi-asserted-by":"crossref","unstructured":"Heiligenhaus A et al. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford). 2007;46(1015\u20131019).","DOI":"10.1093\/rheumatology\/kem053"},{"key":"437_CR5","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1542\/peds.2006-0421","volume":"117","author":"J Cassidy","year":"2006","unstructured":"Cassidy J, Kivlin J, Lindsley C, Nocton J. Ophthalmologic examinations in children with juvenile rheumatoid arthritis. Pediatrics. 2006;117:1843\u20135.","journal-title":"Pediatrics"},{"key":"437_CR6","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1136\/bjo.87.7.879","volume":"87","author":"J Boer De","year":"2003","unstructured":"De Boer J, Wulffraat N, Rothova A. Visual loss in uveitis of childhood. Br J Ophthalmol. 2003;87:879\u201384.","journal-title":"Br J Ophthalmol"},{"key":"437_CR7","author":"L Pelegr\u00edn","year":"2013","unstructured":"Pelegr\u00edn L et al. Predictive Value of Selected Biomarkers, Polymorphisms, and Clinical Features for Oligoarticular Juvenile Idiopathic Arthritis-associated Uveitis. Ocul Immunol Inflamm. 2013. doi: 10.3109\/09273948.2013.841495 .","journal-title":"Ocul Immunol Inflamm"},{"key":"437_CR8","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.3899\/jrheum.081318","volume":"36","author":"EB Nordal","year":"2009","unstructured":"Nordal EB et al. Biomarkers of chronic uveitis in juvenile idiopathic arthritis: predictive value of antihistone antibodies and antinuclear antibodies. J Rheumatol. 2009;36:1737\u201343.","journal-title":"J Rheumatol"},{"key":"437_CR9","doi-asserted-by":"crossref","unstructured":"Angeles-Han ST, Yeh S, Vogler LB. Updates on the risk markers and outcomes of severe juvenile idiopathic arthritis-associated uveitis. Int J Clin Rheumtol. 2013(8).","DOI":"10.2217\/ijr.12.83"},{"key":"437_CR10","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1167\/iovs.12-10865","volume":"54","author":"V Kalinina Ayuso","year":"2013","unstructured":"Kalinina Ayuso V et al. Intraocular biomarker identification in uveitis associated with juvenile idiopathic arthritis. Invest Ophthalmol Vis Sci. 2013;54:3709\u201320.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"437_CR11","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/acr.21674","volume":"64","author":"A Heiligenhaus","year":"2012","unstructured":"Heiligenhaus A et al. Proposed outcome measures for prospective clinical trials in juvenile idiopathic arthritis-associated uveitis: a consensus effort from the multinational interdisciplinary working group for uveitis in childhood. Arthritis Care Res (Hoboken). 2012;64:1365\u201372. Proposed core set of outcome measures for clinical trials in JIA-uveitis that have reached consensus by an international multidisciplinary working group of experts in uveitis.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"437_CR12","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.ophtha.2009.12.003","volume":"117","author":"JE Thorne","year":"2010","unstructured":"Thorne JE, Woreta FA, Dunn JP, Jabs DA. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology. 2010;117:1436\u201341.","journal-title":"Ophthalmology"},{"key":"437_CR13","first-page":"362","volume":"32","author":"I Foeldvari","year":"2005","unstructured":"Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2005;32:362\u20135.","journal-title":"J Rheumatol"},{"key":"437_CR14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ajo.2010.08.021","volume":"151","author":"V Kalinina Ayuso","year":"2011","unstructured":"Kalinina Ayuso V, van de Winkel EL, Rothova A, de Boer JH. Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis. Am J Ophthalmol. 2011;151:217\u201322.","journal-title":"Am J Ophthalmol"},{"key":"437_CR15","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/112067210701700509","volume":"17","author":"A Heiligenhaus","year":"2007","unstructured":"Heiligenhaus A, Mingels A, Heinz C, Ganser G. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur J Ophthalmol. 2007;17:743\u20138.","journal-title":"Eur J Ophthalmol"},{"key":"437_CR16","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/rheumatology\/kes186","volume":"52","author":"G Simonini","year":"2013","unstructured":"Simonini G, Paudyal P, Jones GT, Cimaz R, Macfarlane GJ. Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. Rheumatology (Oxford). 2013;52:825\u201331. Meta-analysys on efficacy and safety of methotrexate in childhood uveitis, including 135 patients from 9 different studies.","journal-title":"Rheumatology (Oxford)"},{"key":"437_CR17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/bjo.2009.173542","volume":"95","author":"JC Goebel","year":"2011","unstructured":"Goebel JC et al. Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis. Br J Ophthalmol. 2011;95:209\u201313.","journal-title":"Br J Ophthalmol"},{"key":"437_CR18","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00296-011-2126-1","volume":"32","author":"A Heiligenhaus","year":"2012","unstructured":"Heiligenhaus A et al. Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int. 2012;32:1121\u201333. German clinical gidelines for treatment of JIA-uveitis, including a therapeutic algorithm.","journal-title":"Rheumatol Int"},{"key":"437_CR19","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ajo.2008.03.004","volume":"146","author":"SC Teoh","year":"2008","unstructured":"Teoh SC, Hogan AC, Dick AD, Lee RWJ. Mycophenolate mofetil for the treatment of uveitis. Am J Ophthalmol. 2008;146:752\u201360. 760.e1\u20133.","journal-title":"Am J Ophthalmol"},{"key":"437_CR20","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ajo.2009.09.026","volume":"149","author":"E Daniel","year":"2010","unstructured":"Daniel E et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010;149:423\u201332. e1\u20132.","journal-title":"Am J Ophthalmol"},{"key":"437_CR21","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.ophtha.2007.12.011","volume":"115","author":"L Sobrin","year":"2008","unstructured":"Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology. 2008;115:1416\u201321. 1421.e1.","journal-title":"Ophthalmology"},{"key":"437_CR22","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bjo.2006.094698","volume":"91","author":"D Doycheva","year":"2007","unstructured":"Doycheva D, Deuter C, Stuebiger N, Biester S, Zierhut M. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol. 2007;91:180\u20134.","journal-title":"Br J Ophthalmol"},{"key":"437_CR23","doi-asserted-by":"crossref","unstructured":"Chang PY et al. Mycophenolate mofetil monotherapy in the management of paediatric uveitis. Eye (Lond). 2011;25(427\u201335).","DOI":"10.1038\/eye.2011.23"},{"key":"437_CR24","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa041810","volume":"352","author":"E Silverman","year":"2005","unstructured":"Silverman E et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med. 2005;352:1655\u201366.","journal-title":"N Engl J Med"},{"key":"437_CR25","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s10067-013-2315-2","volume":"32","author":"C Molina","year":"2013","unstructured":"Molina C, Modesto C, Mart\u00edn-Begu\u00e9 N, Arnal C. Leflunomide, a valid and safe drug for the treatment of chronic anterior uveitis associated with juvenile idiopathic arthritis. Clin Rheumatol. 2013;32:1673\u20135.","journal-title":"Clin Rheumatol"},{"key":"437_CR26","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ophtha.2006.01.005","volume":"113","author":"P Kahn","year":"2006","unstructured":"Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. 2006;113:860\u20134.e2.","journal-title":"Ophthalmology"},{"key":"437_CR27","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ophtha.2005.09.037","volume":"113","author":"RT Rajaraman","year":"2006","unstructured":"Rajaraman RT, Kimura Y, Li S, Haines K, Chu DS. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology. 2006;113:308\u201314.","journal-title":"Ophthalmology"},{"key":"437_CR28","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1442-9071.2005.01062.x","volume":"33","author":"JC Richards","year":"2005","unstructured":"Richards JC, Tay-Kearney M-L, Murray K, Manners P. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Exp Ophthalmol. 2005;33:461\u20138.","journal-title":"Clin Exp Ophthalmol"},{"key":"437_CR29","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/ard.2006.058248","volume":"66","author":"P Tynj\u00e4l\u00e4","year":"2007","unstructured":"Tynj\u00e4l\u00e4 P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis. 2007;66:548\u201350.","journal-title":"Ann Rheum Dis"},{"key":"437_CR30","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3899\/jrheum.120583","volume":"40","author":"ME Zannin","year":"2013","unstructured":"Zannin ME et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol. 2013;40:74\u20139. Data from the National Italian Registryincludes 108 children with JIA-uveitis treated with infliximab or adalimumab.","journal-title":"J Rheumatol"},{"key":"437_CR31","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ophtha.2013.07.019","volume":"121","author":"JN Kruh","year":"2014","unstructured":"Kruh JN, Yang P, Suelves AM, Foster CS. Infliximab for the treatment of refractory noninfectious Uveitis: a study of 88 patients with long-term follow-up. Ophthalmology. 2014;121:358\u201364.","journal-title":"Ophthalmology"},{"key":"437_CR32","doi-asserted-by":"crossref","unstructured":"Sukumaran S, Marzan K, Shaham B, Reiff A. High dose infliximab in the treatment of refractory uveitis: does dose matter? ISRN Rheumatol. 2012;2012(765380).","DOI":"10.5402\/2012\/765380"},{"key":"437_CR33","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.3899\/jrheum.130133","volume":"40","author":"A Tambralli","year":"2013","unstructured":"Tambralli A et al. High doses of infliximab in the management of juvenile idiopathic arthritis. J Rheumatol. 2013;40:1749\u201355.","journal-title":"J Rheumatol"},{"key":"437_CR34","doi-asserted-by":"crossref","unstructured":"Simonini G et al. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis. Rheumatology (Oxford). 2008;47(1510\u20134).","DOI":"10.1093\/rheumatology\/ken298"},{"key":"437_CR35","first-page":"B4616","volume":"60","author":"C Steenholdt","year":"2013","unstructured":"Steenholdt C. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn\u2019s disease. Dan Med J. 2013;60:B4616.","journal-title":"Dan Med J"},{"key":"437_CR36","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jaapos.2013.06.009","volume":"17","author":"L Bravo-Ljubetic","year":"2013","unstructured":"Bravo-Ljubetic L, Peralta-Calvo J, Noval S, Pastora-Salvador N, Abelairas-G\u00f3mez J. Adalimumab therapy for refractory childhood uveitis. J AAPOS. 2013;17:456\u20139.","journal-title":"J AAPOS"},{"key":"437_CR37","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.2147\/OPTH.S23646","volume":"5","author":"K Kotaniemi","year":"2011","unstructured":"Kotaniemi K, S\u00e4il\u00e4 H, Kautiainen H. Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol. 2011;5:1425\u20139.","journal-title":"Clin Ophthalmol"},{"key":"437_CR38","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/bjophthalmol-2011-301401","volume":"97","author":"BC Dobner","year":"2013","unstructured":"Dobner BC et al. A three-centre experience with adalimumab for the treatment of non-infectious uveitis. Br J Ophthalmol. 2013;97:134\u20138.","journal-title":"Br J Ophthalmol"},{"key":"437_CR39","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jpeds.2006.04.058","volume":"149","author":"LB Vazquez-Cobian","year":"2006","unstructured":"Vazquez-Cobian LB, Flynn T, Lehman TJA. Adalimumab therapy for childhood uveitis. J Pediatr. 2006;149:572\u20135.","journal-title":"J Pediatr"},{"key":"437_CR40","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/bjo.2006.103721","volume":"91","author":"S Biester","year":"2007","unstructured":"Biester S et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007;91:319\u201324.","journal-title":"Br J Ophthalmol"},{"key":"437_CR41","doi-asserted-by":"crossref","unstructured":"Tynj\u00e4l\u00e4 P et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford). 2008;47(339\u201344).","DOI":"10.1093\/rheumatology\/kem356"},{"key":"437_CR42","doi-asserted-by":"crossref","first-page":"560632","DOI":"10.1155\/2013\/560632","volume":"2013","author":"C Garc\u00eda-De-Vicu\u00f1a","year":"2013","unstructured":"Garc\u00eda-De-Vicu\u00f1a C et al. Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis. Mediat Inflamm. 2013;2013:560632. Results from a multicentric study of 39 children with uveitis associated with JIA treated with adalimumab.","journal-title":"Mediat Inflamm"},{"key":"437_CR43","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00417-013-2275-x","volume":"251","author":"A Magli","year":"2013","unstructured":"Magli A et al. Adalimumab for juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol. 2013;251:1601\u20136.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"437_CR44","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1745-6215-15-14","volume":"15","author":"A Ramanan","year":"2014","unstructured":"Ramanan A. V et al. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). Trials. 2014;15:14.","journal-title":"Trials"},{"key":"437_CR45","doi-asserted-by":"crossref","unstructured":"Simonini G et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken). 2011;63(612\u20138).","DOI":"10.1002\/acr.20404"},{"key":"437_CR46","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/bjophthalmol-2013-303935","volume":"98","author":"D Doycheva","year":"2014","unstructured":"Doycheva D et al. Immunomodulatory therapy with tumour necrosis factor \u03b1 inhibitors in children with antinuclear antibody-associated chronic anterior uveitis: long-term results. Br J Ophthalmol. 2014;98:523\u20138.","journal-title":"Br J Ophthalmol"},{"key":"437_CR47","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359:810\u201320.","journal-title":"N Engl J Med"},{"key":"437_CR48","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/art.20904","volume":"53","author":"JA Smith","year":"2005","unstructured":"Smith JA et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005;53:18\u201323.","journal-title":"Arthritis Rheum"},{"key":"437_CR49","doi-asserted-by":"crossref","unstructured":"Saurenmann RK et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford). 2006;45(982\u20139).","DOI":"10.1093\/rheumatology\/kel030"},{"issue":"Suppl 1","key":"437_CR50","first-page":"S55","volume":"66","author":"JH Leu","year":"2014","unstructured":"Leu JH et al. A36: Long-term Pharmacokinetics of Body Surface Area-Adjusted Doses of Golimumab Following Repeated Subcutaneous Administrations in Pediatric Patients With Polyarticular Juvenile Idiopathic Arthritis. Arthritis Rheumatol (Hoboken, NJ). 2014;66 Suppl 1:S55\u20136.","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"Suppl 1","key":"437_CR51","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1002\/art.38569","volume":"66","author":"H Brunner","year":"2014","unstructured":"Brunner H et al. A148: a multi-center, double-blind, randomized-withdrawal trial of subcutaneous golimumab in pediatric patients with active polyarticular course juvenile idiopathic arthritis despite methotrexate therapy: week 48 results. Arthritis Rheumatol (Hoboken, NJ). 2014;66 Suppl 1:S191\u20132.","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"437_CR52","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12348-012-0081-y","volume":"2","author":"M William","year":"2012","unstructured":"William M, Faez S, Papaliodis GN, Lobo A-M. Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. J Ophthal Inflamm Infect. 2012;2:231\u20133.","journal-title":"J Ophthal Inflamm Infect"},{"key":"437_CR53","doi-asserted-by":"crossref","first-page":"1892.e3","DOI":"10.1016\/j.ophtha.2011.05.019","volume":"118","author":"M Cordero-Coma","year":"2011","unstructured":"Cordero-Coma M, Salom D, D\u00edaz-Llopis M, L\u00f3pez-Prats MJ, Calleja S. Golimumab for uveitis. Ophthalmology. 2011;118:1892.e3\u20134.","journal-title":"Ophthalmology"},{"key":"437_CR54","first-page":"320","volume":"31","author":"E Miserocchi","year":"2013","unstructured":"Miserocchi E, Modorati G, Pontikaki I, Meroni P, Gerloni V. Golimumab treatment for complicated uveitis. Clin Exp Rheumatol. 2013;31:320\u20131.","journal-title":"Clin Exp Rheumatol"},{"key":"437_CR55","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3109\/09273948.2013.844265","volume":"22","author":"E Miserocchi","year":"2013","unstructured":"Miserocchi E, Modorati G, Pontikaki I, Meroni PL, Gerloni V. Long-term Treatment with Golimumab for Severe Uveitis. Ocul Immunol Inflamm. 2013;22:90\u20135.","journal-title":"Ocul Immunol Inflamm"},{"key":"437_CR56","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3899\/jrheum.120010","volume":"39","author":"C Tappeiner","year":"2012","unstructured":"Tappeiner C, Heinz C, Ganser G, Heiligenhaus A. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol. 2012;39:1294\u20135.","journal-title":"J Rheumatol"},{"key":"437_CR57","author":"A Ad\u00e1n","year":"2013","unstructured":"Ad\u00e1n A, Mesquida M, Lloren\u00e7 V, Modesto C. Tocilizumab for retinal vasoproliferative tumor secondary to juvenile idiopathic arthritis-associated uveitis: a case report. Graefes Arch Clin Exp Ophthalmol. 2013. doi: 10.1007\/s00417-013-2466-5 .","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"437_CR58","unstructured":"An Open-label Trial to Assess the Efficacy and Safety of Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Vision-threatening Uveitis That is Refractory to Other Modes of Systemic Immunosuppression. at http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01603355 ."},{"key":"437_CR59","unstructured":"Angeles-han S, Flynn T, Lehman T. Abatacept for Refractory Juvenile Idiopathic Arthritis-Associated Uveitis \u2212\u2212 A Case Report. J Rheumatol. 2008(35)."},{"key":"437_CR60","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/acr.20359","volume":"63","author":"M Elhai","year":"2011","unstructured":"Elhai M, Deslandre CJ, Kahan A. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article by Zulian et al. Arthritis Care Res (Hoboken). 2011;63:307\u20138. author reply 308.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"437_CR61","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00417-010-1523-6","volume":"249","author":"N Kenawy","year":"2011","unstructured":"Kenawy N et al. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol. 2011;249:297\u2013300.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"437_CR62","doi-asserted-by":"crossref","unstructured":"Zulian F et al. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken). 2010;62(821\u20135).","DOI":"10.1002\/acr.20115"},{"key":"437_CR63","unstructured":"An Openlabel, Phase II Trial of Abatacept (Orencia) in the Treatment of Refractory Non-infectious Uveitis. at http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01279954 ."},{"key":"437_CR64","doi-asserted-by":"crossref","unstructured":"Heiligenhaus A, Miserocchi E, Heinz C, Gerloni V, Kotaniemi K. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford). 2011;50(1390\u20131394).","DOI":"10.1093\/rheumatology\/ker107"},{"key":"437_CR65","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.autrev.2011.07.001","volume":"11","author":"E Miserocchi","year":"2011","unstructured":"Miserocchi E et al. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev. 2011;11:35\u20139.","journal-title":"Autoimmun Rev"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-014-0437-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-014-0437-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-014-0437-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,11]],"date-time":"2019-08-11T18:26:51Z","timestamp":1565548011000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-014-0437-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,18]]},"references-count":65,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["437"],"URL":"https:\/\/doi.org\/10.1007\/s11926-014-0437-4","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,18]]},"article-number":"437"}}